Leukemia
Preliminary results from the ongoing ALPINE study suggest that zanubrutinib may have superior efficacy and an improved safety profile compared with ibrutinib in previously treated patients with chronic lymphocytic leukemia. Read More ›
Results from the 4-year follow-up of the ELEVATE-TN study support acalabrutinib with or without immunotherapy in previously untreated patients with chronic lymphocytic leukemia. Read More ›
Being diagnosed with cancer and undergoing subsequent treatment can be challenging for patients and their partners, but intimacy does not have to end. Read More ›
In June 2021, the FDA approved Rylaze (asparaginase erwinia chrysanthemi [recombinant]-rywn), an asparagine-specific enzyme, to be used as part of a multi-drug chemotherapy regimen for patients older than 1 month with acute lymphoblastic leukemia or lymphoblastic lymphoma who are hypersensitive to asparaginase caused by E. coli infection. Read More ›
Ongoing clinical trials are poised to expand the role of acalabrutinib in treating chronic lymphocytic leukemia. Read More ›
Chronic lymphocytic leukemia can have a negative effect on patients’ quality of life, but healthcare teams may be able to minimize the impact. Read More ›
Low-dose chemoimmunotherapy may be an effective first-line therapy for certain patients with chronic lymphocytic leukemia and particular biological and genetic features. Read More ›
By keeping themselves physically and emotionally healthy, caregivers can give their loved ones the best possible support when helping to care for them. Read More ›
George Valentine was diagnosed with chronic lymphocytic leukemia in 2002. He shares some of his hard-learned tips on how to deal with a cancer diagnosis and the high costs of treatment. Read More ›